Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Watch phosphate through refeeding
Main human AOD-9604 treatment timelines Study METAOD004 Participants 36 Route Oral Treatment length 7 days Dose range 9, 27, or 54 mg/day Main lesson Short safety and tolerability study Study METAOD005 Participants 300 Route Oral Treatment length 12 weeks Dose range 1 to 30 mg/day Main lesson Earlier weight-loss trial with a non-linear dose response Study METAOD006 Participants 502 randomized Route Oral Treatment length 24 weeks Dose range 0.25, 0.5, or 1 mg/day Main lesson Primary weight-loss goal was not met The oral milligram doses in these trials cannot be converted into subcutaneous microgram doses
Wegovy and Ozempic contain the same active ingredient, semaglutide, but they are prescribed for different purposes
Our care model is designed to address boththoughtfully, safely, and with close medical support
